Josh Caddy

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

Chulin Sha, Sharon Barrans, Francesco Cucco et al. · Journal of Clinical Oncology · 2018 · 301 citations · Full text

Medicine, Hematology, Oncology +17

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Andrew Davies, Thomas Cummin, Sharon Barrans et al. · The Lancet Oncology · 2019 · 272 citations · Full text

Medicine, Hematology, Oncology +15

Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit

Francesco Cucco, Sharon Barrans, Chulin Sha et al. · Leukemia · 2019 · 117 citations · Full text

Medicine, Genetics, Oncology +17

Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up

Andrew Davies, Sharon Barrans, Louise Stanton et al. · Journal of Clinical Oncology · 2023 · 77 citations · Full text

Medicine, Hematology, Oncology +16

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Andrew Davies, Josh Caddy, Tom Maishman et al. · Blood · 2015 · 28 citations

Medicine, Molecular Medicine, Oncology +10